Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Insider & Institutional Ownership
1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Jupiter Neurosciences and Shionogi & Co., Ltd. Unsponsored ADR”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jupiter Neurosciences | $20,000.00 | 131.22 | -$8.65 million | ($19.12) | -0.15 |
| Shionogi & Co., Ltd. Unsponsored ADR | $3.32 billion | 4.46 | $1.35 billion | $1.00 | 8.69 |
Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Jupiter Neurosciences and Shionogi & Co., Ltd. Unsponsored ADR, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jupiter Neurosciences | 1 | 0 | 0 | 0 | 1.00 |
| Shionogi & Co., Ltd. Unsponsored ADR | 0 | 1 | 0 | 2 | 3.33 |
Volatility & Risk
Jupiter Neurosciences has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.
Profitability
This table compares Jupiter Neurosciences and Shionogi & Co., Ltd. Unsponsored ADR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jupiter Neurosciences | N/A | N/A | -246.66% |
| Shionogi & Co., Ltd. Unsponsored ADR | 46.67% | 16.13% | 12.09% |
Summary
Shionogi & Co., Ltd. Unsponsored ADR beats Jupiter Neurosciences on 10 of the 13 factors compared between the two stocks.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
